Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells

BACKGROUND: Patients affected by aggressive B-cell malignancies who are resistant to primary or salvage chemoimmunotherapy have an extremely poor prognosis and limited therapeutic options. Promising therapeutic success has been achieved with the infusion of CD19 chimeric antigen receptor-T cells, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietà, Anna Dalla, Cappuzzello, Elisa, Palmerini, Pierangela, Ventura, Annavera, Visentin, Andrea, Astori, Giuseppe, Chieregato, Katia, Mozzo, Valentina, Perbellini, Omar, Tisi, Maria Chiara, Trentin, Livio, Visco, Carlo, Ruggeri, Marco, Sommaggio, Roberta, Rosato, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287629/
https://www.ncbi.nlm.nih.gov/pubmed/34272306
http://dx.doi.org/10.1136/jitc-2021-002475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287629/
https://www.ncbi.nlm.nih.gov/pubmed/34272306
http://dx.doi.org/10.1136/jitc-2021-002475

Ejemplares similares